Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
United Therapeutics Says FDA Accepts Supplemental Filing for Nebulized Tyvaso in IPF

United Therapeutics Says FDA Accepts Supplemental Filing for Nebulized Tyvaso in IPF

MT newswireMT newswire2026/09/02 11:25
07:25 AM EDT, 09/02/2026 (MT Newswires) -- United Therapeutics (UTHR) said Wednesday the US Food and Drug Administration has accepted its supplemental new drug application for nebulized Tyvaso inhalation solution to treat idiopathic pulmonary fibrosis, or IPF. The application was based on the combined analyses of the results of two phase 3 studies that showed nebulized Tyvaso demonstrated "statistically significant superiority" over placebo, the company said. United Therapeutics said it expects the FDA to complete its review of the application in late April 2027.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Japan's 20-year government bond auction sees weak demand as bid-to-cover ratio drops sharply to 3.64, marking the lowest demand of the year

Japan's 20-year government bond auction saw weak demand, with the bid-to-cover ratio falling to 3.64 and the tail widening to its largest in a year. The market is concerned about fiscal budget issues and rising yields.

智通财经•2026/11/18 06:52
Japan's 20-year government bond auction sees weak demand as bid-to-cover ratio drops sharply to 3.64, marking the lowest demand of the year

Google-backed AI pharmaceutical company raises $5 billion in funding, doubling the previous round

The current funding round for Isomorphic Labs is co-led by top VCs including Sequoia Capital and Andreessen Horowitz. This round comes only six months after the previous $2.1 billion Series B, with the scale more than doubling. By 2026, total financing in the AI pharmaceutical sector has reached a record high of $23.2 billion, with Anthropic and OpenAI also entering the field.

华尔街见闻•2026/11/18 06:51

Japanese stocks closed up by 0.28%

格隆汇•2026/11/18 06:39
Japanese stocks closed up by 0.28%

Report: Apple Plans to Establish Multi-Year DRAM Agreement with Samsung, Deliveries to Begin in First Half of 2027

Apple and Samsung are in negotiations for a long-term DRAM chip supply agreement lasting four to five years, with deliveries expected to start in the first half of 2027. The agreement is expected to include a minimum supply commitment and set pricing linked to the market. Currently, Apple is one of the few major tech companies that have yet to sign a long-term DRAM supply deal with Samsung.

华尔街见闻•2026/11/18 06:31
Report: Apple Plans to Establish Multi-Year DRAM Agreement with Samsung, Deliveries to Begin in First Half of 2027